Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial
COVID-19
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring Ivermectin, Colchecine, COVID-19
Eligibility Criteria
Inclusion Criteria: Participants aged (18-64) years with confirmed criteria of COVID-19 infection. Moderate Cases: Patients have symptoms (such as fever, respiratory tract symptoms), pneumonic manifestations can be seen in chest imaging and oxygen saturation more than 94% (Egyptian Ministry of Health and Population, 2020). Exclusion Criteria: Pregnant or lactating female. Any co-morbidities (DM, hypertension, Asthma……etc.). Participants receiving immunosuppressive or chemotherapy drugs. Active malignancy.
Sites / Locations
- Ain shams university
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
Ivermectin group
Colchicine group
Control group
received standard treatment plus Ivermectin in the form of oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days
received standard treatment plus Colchicine 0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
received the standard treatment according to the protocol of the Egyptian Supreme Council of University Hospitals (http://scu.eg/pages/university_hospitals) (Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks and needed protocol of management according to case assessment and severity)